T cells are a critical part of the adaptive immune system that are able to distinguish between
healthy and unhealthy cells. Upon recognition of protein fragments (peptides), activated T …

Adaptive immune recognition is mediated by specific interactions between heterodimeric T
cell receptors (TCRs) and their cognate peptide-MHC (pMHC) ligands, and the methods to …

The T cells of the immune system can target tumors and clear solid cancers following tumor-
infiltrating lymphocyte (TIL) therapy. We used combinatorial peptide libraries and a …

The ability to decode antigen specificities encapsulated in the sequences of rearranged T-
cell receptor (TCR) genes is critical for our understanding of the adaptive immune system …

Adoptive transfer of T cells genetically modified to express a cancer-specific T-cell receptor
(TCR) has shown significant therapeutic potential for both hematological and solid tumors …

Short, synthetic peptides that are displayed by major histocompatibility complex I (MHC I)
can stimulate CD8 T cells in vivo to destroy virus-infected or cancer cells. The development …

T cell receptor (TCR)–engineered T cell therapy using high-affinity TCRs is a promising
treatment modality for cancer. Discovery of high-affinity TCRs especially against self …

Since the commercialization of the first liposomes used for drug delivery, Doxil/Caelyx® and
Myocet®, tremendous progress has been made in understanding interactions between …

Over the last several years, there has been considerable progress in the treatment of cancer
using gene modified adoptive T cell therapies. Two approaches have been used, one …

Primary antibody deficiencies, such as common variable immunodeficiency (CVID), are
heterogenous disease entities consisting of primary hypogammaglobulinemia and impaired …